sibutramine and Diabetes Mellitus, Adult-Onset studies

sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride

Research Excerpts

Excerpt	Relevance	Reference
"The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality."	9.16	Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012)
"To evaluate the effects of one year of treatment with sibutramine plus L-carnitine compared to sibutramine on body weight, glycemic control, and insulin resistance state in type 2 diabetic patients."	9.14	Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010)
"We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events."	9.14	Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010)
"Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients."	9.14	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2010)
" We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population."	9.14	Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009)
" The effect of sibutramine combined with hypocaloric diet and exercise on body weight, body fat mass, lipids, glycemic control, insulin secretion and insulin resistance was evaluated in a randomized, controlled, open-label study."	9.11	Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. ( Dakovska, G; Dakovska, L; Kirilov, G; Koev, D; Lazarova, M; Tankova, T, 2004)
"To assess the efficacy and tolerability of sibutramine 15 mg once daily as a weight reduction agent in overweight and obese patients (body mass index (b."	9.09	Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. ( Banks, LM; Bloom, SR; Finer, N; Frost, GS; Griffiths, J, 2000)
") > or =27 kg/m2) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53."	9.09	Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. ( Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000)
"Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity."	8.82	Sibutramine and the management of obesity. ( Foreyt, JP; Poston, WS, 2004)
" After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance."	8.81	New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. ( Ernest, P; Scheen, AJ, 2002)
" For subjects who had failed to lose weight via the 'Lifestyle' intervention, the addition of sibutramine resulted in a similar weight loss compared to their pair-matched 'Lifestyle' only 'successful' counterparts (9."	7.74	Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox. ( Barratt, R; Frost, G; Millward, J; O'Boyle, A; Truby, H, 2008)
"Among methods of treatment of obesity the most known and safe is the low calories content diet."	6.42	[Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia]. ( Kawecka-Jaszcz, K; Rajzer, M; Wojciechowska, W, 2004)
"Weight reduction is also a cornerstone of diabetes management, improving glycaemic control and reducing other risk factors associated with this disease."	6.41	The importance of obesity in diabetes and its treatment with sibutramine. ( Peiffer, FW; Van Gaal, LF, 2001)
"The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise."	5.19	Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. ( Caterson, ID; Coutinho, W; Espinoza, D; Finer, N; Gebski, V; Ivers, L; James, WP; Legler, UF; Seimon, RV; Sharma, AM, 2014)
"This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized to lifestyle intervention with or without sibutramine for up to 6 years."	5.17	Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013)
"The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality."	5.16	Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012)
"The aim of the study was to evaluate the effects of 12-month treatment with sibutramine plus L-carnitine compared with sibutramine alone on body weight, glycemic control, insulin resistance, and inflammatory state in type 2 diabetes mellitus patients."	5.15	Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2011)
"We observed a decrease of body weight after 9 and 12 months in the group treated with sibutramine, but not in the control group."	5.15	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2011)
" We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population."	5.14	Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009)
"To evaluate the effects of one year of treatment with sibutramine plus L-carnitine compared to sibutramine on body weight, glycemic control, and insulin resistance state in type 2 diabetic patients."	5.14	Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010)
"We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events."	5.14	Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010)
"Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients."	5.14	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2010)
"To assess the efficacy of sibutramine 15 mg once daily as weight reduction in overweight and obese (body mass index > 25 kg/m2) Chinese female type 2 diabetic patients and to evaluate the influence of weight loss on diabetic control, a randomised, double-blind, placebo-control, 12-week study was conducted."	5.11	Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. ( Chang, ET; Hsieh, MC; Kuo, SW; Li, JC; Pei, D; Su, KY; Tsai, CC; Tsai, WC; Wang, TF; Yao, CY, 2005)
"This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors."	5.11	Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. ( Gaciong, Z; Placha, G, 2005)
"After 6 months of sibutramine treatment statistically significant changes from baseline were observed for body weight (85."	5.11	Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. ( Chen, YC; Fan, SC; He, CT; Hsieh, CH; Hung, YJ; Kuo, SW; Lee, CH; Pei, D; Sheu, WH; Wu, LY, 2005)
"In this population of obese Hispanic patients with type 2 diabetes, sibutramine combined with glibenclamide therapy achieved weight loss for up to 12 months and was associated with better glycemic control than placebo."	5.11	Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. ( Berber, A; Campos-Franco, E; Fanghänel, G; Martínez-Rivas, L; Sánchez-Reyes, L; Yamamoto, J, 2004)
"Both orlistat and sibutramine were effective on anthropometric variables and on metabolic pattern during the 12-month treatment; in our sample, orlistat appears to be slightly more efficacious as an anti-obesity drug, while sibutramine intake was not associated to any cardiovascular effect and was generally better tolerated than orlistat."	5.11	Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Murdolo, G, 2004)
" The effect of sibutramine combined with hypocaloric diet and exercise on body weight, body fat mass, lipids, glycemic control, insulin secretion and insulin resistance was evaluated in a randomized, controlled, open-label study."	5.11	Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. ( Dakovska, G; Dakovska, L; Kirilov, G; Koev, D; Lazarova, M; Tankova, T, 2004)
"The mean weight loss was greater in the sibutramine group (-7."	5.11	Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. ( Kaukua, JK; Pekkarinen, TA; Rissanen, AM, 2004)
"To investigate whether the satiety-inducing agent sibutramine affected body weight and associated anthropometry in overweight and obese (body mass index (BMI) > 27) Type 2 diabetic patients on sulphonylurea therapy."	5.10	Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. ( Melchionda, N; Moreno-Carretero, E; Serrano-Rios, M, 2002)
"To assess the efficacy and tolerability of sibutramine 15 mg once daily as a weight reduction agent in overweight and obese patients (body mass index (b."	5.09	Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. ( Banks, LM; Bloom, SR; Finer, N; Frost, GS; Griffiths, J, 2000)
") > or =27 kg/m2) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53."	5.09	Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. ( Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000)
"An open, non-comparative study was carried out to assess the efficacy and toleration profile of sibutramine, a new antiobesity drug, in promoting weight loss in obese type 2 diabetes mellitus subject who failed to reduce weight after strict dietary control."	5.09	Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management. ( Kumar, A; Lal, M; Sircar, AR, 2001)
" Sibutramine is a serotonin-noradrenaline reuptake inhibitor, which acts centrally by promoting the feeling of satiety and decreasing caloric intake, thus resulting in weight loss."	4.85	Effect of antiobesity medications in patients with type 2 diabetes mellitus. ( Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET, 2009)
"Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 26 to 52 weeks."	4.82	Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. ( Avenell, A; Gregg, E; Kim, C; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2004)
"Weight loss with sibutramine treatment is associated with improved insulin sensitivity and a fall in glycosylated haemoglobin levels in type 2 diabetic patients."	4.82	A review of the metabolic effects of sibutramine. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005)
"Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity."	4.82	Sibutramine and the management of obesity. ( Foreyt, JP; Poston, WS, 2004)
"Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks."	4.82	Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. ( Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2005)
" After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance."	4.81	New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. ( Ernest, P; Scheen, AJ, 2002)
" For subjects who had failed to lose weight via the 'Lifestyle' intervention, the addition of sibutramine resulted in a similar weight loss compared to their pair-matched 'Lifestyle' only 'successful' counterparts (9."	3.74	Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox. ( Barratt, R; Frost, G; Millward, J; O'Boyle, A; Truby, H, 2008)
"Sibutramine (Reductil, Abbott-Knoll, 10 mg and 15 mg) is a new appetite regulator recommended in the treatment of obesity."	3.71	[Pharma-clinics. Medication of the month. Sibutramine (Reductil)]. ( Scheen, AJ, 2001)
"Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day)."	2.74	Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Piccinni, MN; Salvadeo, SA, 2009)
"Sibutramine treatment raised sitting diastolic blood pressure by > or = 5 mmHg in a higher proportion of patients than did placebo (43% with 15 mg/day vs."	2.71	A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. ( McNulty, SJ; Ur, E; Williams, G, 2003)
"Obese patients with type 2 diabetes mellitus enrolled in an ongoing double-blind, placebo-controlled, parallel-arm, 12-month study of sibutramine (followed by a 12-month open label extension) underwent transthoracic echocardiographic imaging and color Doppler interrogation for assessment of cardiac valve anatomy and function."	2.69	Absence of cardiac valve dysfunction in obese patients treated with sibutramine. ( Armstrong, WF; Bach, DS; Kelly, F; Mendel, CM; Patel, B; Pekkarinen, TA; Rissanen, AM; Seaton, TB; Shepherd, G; Weinstein, SP, 1999)
"While treating obesity, those conditions are also managed."	2.49	Obesity drug therapy. ( Baretić, M, 2013)
"For sibutramine, higher on-treatment elevations in SBP (1."	2.46	Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. ( Johansson, K; Neovius, K; Neovius, M; Rössner, S; Sundström, J, 2010)
"Obesity increases the risk of type 2 diabetes."	2.44	Pharmacotherapy for obesity in menopausal women. ( Barnett, A; Rahim, A; Samat, A, 2008)
"Most patients with type 2 diabetes mellitus are overweight or obese, and the relation between obesity, especially of the visceral compartment, and the risk for developing diabetes is well recognized."	2.44	Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. ( Aronne, LJ; Lee, M, 2007)
"Obesity infrequently associated with type 2 diabetes mellitus and may cause insulin resistance, hypertension and other complications of obesity."	2.42	Obesity management in patients with type 2 diabetes mellitus. ( Mannan, MA; Rahman, MS; Siddiqui, NI, 2004)
"Obesity is the most important modifiable risk factor for type 2 diabetes mellitus and most patients with diabetes are overweight or obese."	2.42	Managing type 2 diabetes mellitus in patients with obesity. ( Hauner, H, 2004)
"Among methods of treatment of obesity the most known and safe is the low calories content diet."	2.42	[Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia]. ( Kawecka-Jaszcz, K; Rajzer, M; Wojciechowska, W, 2004)
"Sibutramine has actions on both energy intake and expenditure and had been shown to enhance weight loss and weight maintenance achieved by diet, in simple obesity as well as when accompanied by complications of diabetes or hypertension."	2.41	Pharmacotherapy of obesity. ( Finer, N, 2002)
"Obesity is a growing public health problem worldwide."	2.41	Obesity: a rational target for managing diabetes mellitus. ( Mooradian, AD, 2001)
"Overweight and obesity have not only a significant psychological impact but also result in an increased risk for development of numerous chronic and sometimes fatal diseases."	2.41	Epidemiology, morbidity, and treatment of overweight and obesity. ( Aronne, LJ, 2001)
"Weight reduction is also a cornerstone of diabetes management, improving glycaemic control and reducing other risk factors associated with this disease."	2.41	The importance of obesity in diabetes and its treatment with sibutramine. ( Peiffer, FW; Van Gaal, LF, 2001)
"Sibutramine is a centrally acting inhibitor of noradrenaline and serotonine reuptake, thereby decreasing caloric intake and increasing energy expenditure."	2.41	Current pharmacological approaches to the treatment of obesity. ( Hauner, H, 2001)
"Obesity is a major risk factor for the development of type 2 diabetes and is an important obstacle to the management of this disease."	2.40	Obesity and type 2 diabetes: a conflict of interests? ( Williams, G, 1999)
"Sibutramine is a centrally acting serotonin/noradrenaline reuptake inhibitor that mainly increases satiety."	1.35	[Pharmacological therapy of obesity]. ( Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V, 2008)
"Obesity is frequently associated with other pathologies: cardiovascular, oncologic, systemic (diabetes) or oral."	1.35	[Obesity and oral health: risk factors of obese patients in dental practice]. ( Godlewski, AE; Nicolas, E; Veyrune, JL, 2008)
"Obesity is a major health problem in the United States and many other countries because of its high prevalence and causal relationship with serious medical comorbidities."	1.35	Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery. ( Fabbrini, E; Klein, S, 2008)

Research

Studies (68)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Risk of Death From Any Cause (All-cause Mortality)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (4.41)	18.2507
2000's	52 (76.47)	29.6817
2010's	13 (19.12)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Ghotbi, AA	1
Køber, L	2
Finer, N	10
James, WP	7
Sharma, AM	8
Caterson, I	2
Coutinho, W	8
Van Gaal, LF	5
Torp-Pedersen, C	7
Andersson, C	2
Baretić, M	1
Seimon, RV	1
Espinoza, D	1
Ivers, L	1
Gebski, V	1
Legler, UF	2
Caterson, ID	6
Samat, A	1
Rahim, A	1
Barnett, A	1
Van Gaal, L	2
Maggioni, AP	5
Bacher, HP	1
Shepherd, GM	4
Pagotto, U	1
Vanuzzo, D	1
Vicennati, V	1
Pasquali, R	1
Derosa, G	7
D'Angelo, A	6
Salvadeo, SA	4
Ferrari, I	6
Gravina, A	4
Fogari, E	1
Maffioli, P	6
Cicero, AF	7
Gaal, LV	1
Bacher, P	1
Shepherd, G	2
Sun, R	1
James, P	1
Fabbrini, E	1
Klein, S	1
Choussein, S	1
Makri, AA	1
Frangos, CC	1
Petridou, ET	1
Daskalopoulou, SS	1
Mereu, R	3
Ciccarelli, L	2
Piccinni, MN	1
Godlewski, AE	1
Veyrune, JL	1
Nicolas, E	1
Weeke, P	1
Fosbøl, EL	1
Brendorp, B	1
Rode, RA	3
Ge, H	1
Moran, SA	1
Johansson, K	1
Sundström, J	1
Neovius, K	1
Rössner, S	1
Neovius, M	1
Palumbo, I	4
Randazzo, S	4
Renz, CL	2
Perdok, RJ	1
Kachowski, L	1
Over, DR	1
Qiu, K	1
Colman, E	1
Matiba, B	2
McNulty, SJ	1
Ur, E	1
Williams, G	2
Scheen, AJ	2
Ernest, P	1
Haynes, WG	1
Peter, P	1
Kumar, S	1
Mannan, MA	1
Rahman, MS	1
Siddiqui, NI	1
Kaukua, JK	1
Pekkarinen, TA	2
Rissanen, AM	2
Poston, WS	1
Foreyt, JP	1
Rajzer, M	1
Wojciechowska, W	1
Kawecka-Jaszcz, K	1
Norris, SL	2
Zhang, X	2
Avenell, A	2
Gregg, E	2
Schmid, CH	2
Kim, C	1
Lau, J	2
Sánchez-Reyes, L	1
Fanghänel, G	1
Yamamoto, J	1
Martínez-Rivas, L	1
Campos-Franco, E	1
Berber, A	1
Murdolo, G	1
Fogari, R	1
Tankova, T	1
Dakovska, G	1
Lazarova, M	1
Dakovska, L	1
Kirilov, G	1
Koev, D	1
Vettor, R	1
Serra, R	1
Fabris, R	1
Pagano, C	1
Federspil, G	1
Filippatos, TD	1
Kiortsis, DN	1
Liberopoulos, EN	1
Mikhailidis, DP	1
Elisaf, MS	1
Gaciong, Z	1
Placha, G	1
Redmon, JB	1
Reck, KP	1
Raatz, SK	1
Swanson, JE	1
Kwong, CA	1
Ji, H	1
Thomas, W	1
Bantle, JP	1
Wang, TF	1
Pei, D	2
Li, JC	1
Tsai, WC	1
Tsai, CC	1
Yao, CY	1
Chang, ET	1
Hsieh, MC	1
Su, KY	1
Kuo, SW	2
Hauner, H	2
Hung, YJ	1
Chen, YC	1
Hsieh, CH	1
Wu, LY	1
He, CT	1
Lee, CH	1
Fan, SC	1
Sheu, WH	1
Kennedy, RL	1
Khoo, EY	1
Brennan, A	1
Ara, R	1
Sterz, R	1
Bergemann, R	1
Lee, M	1
Aronne, LJ	2
Toubro, S	1
Bodary, PF	1
Iglay, HB	1
Eitzman, DT	1
Aylwin, S	1
Al-Zaman, Y	1
Barratt, R	1
Frost, G	1
O'Boyle, A	1
Millward, J	1
Truby, H	1
Rissanen, A	1
Bach, DS	1
Mendel, CM	1
Weinstein, SP	2
Kelly, F	1
Seaton, TB	2
Patel, B	1
Armstrong, WF	1
Davis, JL	1
Bloom, SR	1
Frost, GS	1
Banks, LM	1
Griffiths, J	1
Fujioka, K	1
Rowe, E	1
Jelinek, CA	1
Raskin, P	1
Lebovitz, HE	1
Mooradian, AD	1
Sircar, AR	1
Kumar, A	1
Lal, M	1
Serrano-Rios, M	1
Melchionda, N	1
Moreno-Carretero, E	1
Peiffer, FW	1
Verspohl, EJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event[NCT00234832]	Phase 3	10,777 participants (Actual)	Interventional	2003-01-31	Completed
Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382]	Phase 3	60 participants (Anticipated)	Interventional	2008-11-30	Active, not recruiting
Evaluation of the Effectiveness of Cryotherapy in Slimming of the Abdomen and Saddlebags[NCT04287153]		30 participants (Actual)	Interventional	2017-09-17	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

For each subject who died, the time to death was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

Risk of Experiencing a Nonfatal MI Included in the POE

Intervention	Participants (Number)
Randomized Sibutramine	418
Randomized Placebo	404

For each subject, the first occurrence of a nonfatal MI included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

Risk of Experiencing a Nonfatal Stroke Included in the POE

Intervention	Participants (Number)
Randomized Sibutramine	200
Randomized Placebo	159

For each subject, the time to first occurrence of a nonfatal stroke included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

Risk of Experiencing a POE or a Revascularization Procedure

Intervention	Participants (Number)
Randomized Sibutramine	127
Randomized Placebo	95

This outcome includes nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, CV death (including events such as fatal MI and fatal stroke), and any of the following revascularization procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft, coronary artery stent placement, cardiac transplant, peripheral vascular bypass or angioplasty, and carotid endarterectomy. For each subject, the POE or revascularization status (yes/no) and time to first occurrence of an event using time-to-event analysis were evaluated. (NCT00234832)
Timeframe: From randomization up to 6 years

Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE

Intervention	Participants (Number)
Randomized Sibutramine	927
Randomized Placebo	856

For each subject, the time to first occurrence of a resuscitated cardiac arrest included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

Risk of Experiencing Cardiovascular Death Included in the POE

Intervention	Participants (Number)
Randomized Sibutramine	11
Randomized Placebo	7

For each subject, the time to cardiovascular death included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)

Intervention	Participants (Number)
Randomized Sibutramine	223
Randomized Placebo	229

For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

Intervention	Participants (Number)
	Intent-to-treat population
CV + DM Randomized to Placebo	346
CV + DM Randomized to Sibutramine	403
CV Only Randomized to Placebo	66
CV Only Randomized to Sibutramine	77
DM Only Randomized to Placebo	77
DM Only Randomized to Sibutramine	79
Randomized Placebo	490
Randomized Sibutramine	561

Article	Year
Obesity drug therapy. Minerva endocrinologica, 2013, Volume: 38, Issue:3 Topics: Anti-Obesity Agents; Appetite; Combined Modality Therapy; Comorbidity; Cost-Benefit Analysis; Cyclob	2013
Pharmacotherapy for obesity in menopausal women. Menopause international, 2008, Volume: 14, Issue:2 Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female;	2008
Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabe	2009
Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2010, Volume: 11, Issue:11 Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactone	2010
Pharmacotherapy of obesity. Best practice & research. Clinical endocrinology & metabolism, 2002, Volume: 16, Issue:4 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; History, 20th Ce	2002
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes & metabolism, 2002, Volume: 28, Issue:6 Pt 1 Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Clinical Trials as Topic; Controlled Clini	2002
Medical management of obesity: a clinical imperative? Current diabetes reports, 2003, Volume: 3, Issue:1 Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Diet; Exercise; Humans; Lactones; Life	2003
Obesity management in patients with type 2 diabetes mellitus. Mymensingh medical journal : MMJ, 2004, Volume: 13, Issue:1 Topics: Cyclobutanes; Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Gastric Bypass; Humans; Obesity; We	2004
Sibutramine and the management of obesity. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:3 Topics: Adolescent; Adrenergic Uptake Inhibitors; Appetite Depressants; Cardiovascular System; Clinical Tria	2004
[Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia]. Przeglad lekarski, 2004, Volume: 61, Issue:2 Topics: Animals; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Developed Countries; Diabetes	2004
Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Archives of internal medicine, 2004, Jul-12, Volume: 164, Issue:13 Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Dru	2004
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2005, Jan-25, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetin	2005
Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes care, 2005, Volume: 28, Issue:4 Topics: Appetite Depressants; Body Weight; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Randomized Contr	2005
A review of the metabolic effects of sibutramine. Current medical research and opinion, 2005, Volume: 21, Issue:3 Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus, Type 2; Glycated	2005
Managing type 2 diabetes mellitus in patients with obesity. Treatments in endocrinology, 2004, Volume: 3, Issue:4 Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; D	2004
Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. The American journal of cardiology, 2007, Feb-19, Volume: 99, Issue:4A Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cyclobutanes; Diabet	2007
Strategies to reduce vascular risk associated with obesity. Current vascular pharmacology, 2007, Volume: 5, Issue:4 Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2;	2007
Emerging concepts in the medical and surgical treatment of obesity. Frontiers of hormone research, 2008, Volume: 36 Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria	2008
Pharmacological intervention: the antiobesity approach. European journal of clinical investigation, 1998, Volume: 28 Suppl 2 Topics: Appetite Depressants; Blood Glucose; Controlled Clinical Trials as Topic; Cyclobutanes; Dexfenfluram	1998
Obesity and type 2 diabetes: a conflict of interests? International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1999, Volume: 23 Suppl 7 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Complications; Diabetes Mellitus;	1999
Current pharmacological approaches to the treatment of obesity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25 Suppl 1 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlip	2001
Obesity: a rational target for managing diabetes mellitus. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001, Volume: 11 Suppl A Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactones	2001
Epidemiology, morbidity, and treatment of overweight and obesity. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 23 Topics: Adult; Aged; Antipsychotic Agents; Appetite Depressants; Body Height; Body Mass Index; Body Weight;	2001
Is sibutramine more than a slim hope? Drug and therapeutics bulletin, 2001, Volume: 39, Issue:12 Topics: Adult; Appetite Depressants; Chemotherapy, Adjuvant; Cyclobutanes; Diabetes Mellitus, Type 2; Diet,	2001
The importance of obesity in diabetes and its treatment with sibutramine. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25 Suppl 4 Topics: Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Obesity;	2001
[Weight reduction. Antiobesity drug treatment in type-2 diabetics]. Pharmazie in unserer Zeit, 2002, Volume: 31, Issue:3 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Diabetes	2002

Article	Year
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes care, 2013, Volume: 36, Issue:11 Topics: Aged; Cardiovascular Diseases; Clinical Protocols; Cyclobutanes; Diabetes Mellitus, Type 2; Female;	2013
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. International journal of obesity (2005), 2014, Volume: 38, Issue:9 Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabet	2014
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:3 Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies	2009
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:11 Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cyclobutanes	2008
Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Journal of cardiovascular pharmacology, 2008, Volume: 52, Issue:5 Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabet	2008
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:5 Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double	2009
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism: clinical and experimental, 2009, Volume: 58, Issue:8 Topics: Aged; Appetite Depressants; Bilirubin; Biomarkers; Cardiovascular Diseases; Confounding Factors, Epi	2009
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:1 Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus	2010
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism: clinical and experimental, 2011, Volume: 60, Issue:3 Topics: Aged; Appetite Depressants; Blood Glucose; Body Weight; C-Reactive Protein; Carnitine; Cholesterol;	2011
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:16 Topics: Blood Glucose; Carnitine; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy	2010
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10 Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus	2010
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:5 Topics: Adiponectin; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; C-Reactive Protein;	2011
Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2010, Volume: 13, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; C	2010
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:6 Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind	2012
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes care, 2003, Volume: 26, Issue:1 Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cyclobutanes; Diabetes Mellitus; D	2003
Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004, Volume: 28, Issue:4 Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Complications; Diabetes Mel	2004
Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clinical therapeutics, 2004, Volume: 26, Issue:9 Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Bl	2004
Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes, nutrition & metabolism, 2004, Volume: 17, Issue:4 Topics: Anthropometry; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double-	2004
Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta diabetologica, 2004, Volume: 41, Issue:4 Topics: Adipose Tissue; Adult; Appetite Depressants; Blood Glucose; Body Weight; Cyclobutanes; Diabetes Mell	2004
Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. Journal of human hypertension, 2005, Volume: 19, Issue:9 Topics: Adult; Appetite Depressants; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobutanes; Dia	2005
Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes care, 2005, Volume: 28, Issue:6 Topics: Appetite Depressants; Body Mass Index; Body Weight; Combined Modality Therapy; Cyclobutanes; Diabete	2005
Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. International journal of clinical practice, 2005, Volume: 59, Issue:7 Topics: Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; F	2005
Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:8 Topics: Adiponectin; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Cyc	2005
Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obesity research, 1999, Volume: 7, Issue:4 Topics: Adult; Aged; Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Cyclobutanes; Diabet	1999
Use of sibutramine hydrochloride monohydrate in the treatment of the painful peripheral neuropathy of diabetes. Diabetes care, 2000, Volume: 23, Issue:10 Topics: Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans	2000
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes, obesity & metabolism, 2000, Volume: 2, Issue:2 Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Gluco	2000
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2000, Volume: 2, Issue:3 Topics: Adolescent; Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Diabet	2000
Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management. The Journal of the Association of Physicians of India, 2001, Volume: 49 Topics: Adult; Aged; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Do	2001
Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:2 Topics: Appetite Depressants; Body Mass Index; Body Weight; Cholesterol; Cyclobutanes; Diabetes Mellitus; Di	2002

Article	Year
[Pharmacological therapy of obesity]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagon	2008
Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery. Clinical cornerstone, 2008, Volume: 9, Issue:1 Topics: Anti-Obesity Agents; Bariatric Surgery; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cy	2008
[Obesity and oral health: risk factors of obese patients in dental practice]. Odonto-stomatologie tropicale = Tropical dental journal, 2008, Volume: 31, Issue:123 Topics: Adult; Appetite Depressants; Child; Child, Preschool; Cyclobutanes; Dental Caries; Diabetes Mellitus	2008
FPIN’s clinical inquiries. Medications for weight loss in patients with type 2 diabetes mellitus. American family physician, 2012, Mar-15, Volume: 85, Issue:6 Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetine; Fructose; Humans; Lactones	2012
Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation, 2012, May-01, Volume: 125, Issue:17 Topics: Adolescent; Adult; Advisory Committees; Aged; Anti-Obesity Agents; Bariatric Medicine; Body Mass Ind	2012
[The anti-obesity drug sibutramine for overweight diabetic patients. "Blood pressure is not elevated")]. MMW Fortschritte der Medizin, 2002, Jul-11, Volume: 144, Issue:27-28 Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hu	2002
[Weight loss lowers blood pressure, lipids and blood glucose. Sibutramine also helps diabetics with weight loss]. MMW Fortschritte der Medizin, 2002, Sep-12, Volume: 144, Issue:37 Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus; Diabetes Melli	2002
Management of the overweight patient with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2003, Volume: 20 Suppl 4 Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hum	2003
New options for drug treatment of obesity in patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22 Suppl 4 Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Hu	2005
Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. The European journal of health economics : HEPAC : health economics in prevention and care, 2006, Volume: 7, Issue:4 Topics: Adult; Appetite Depressants; Coronary Disease; Cost-Benefit Analysis; Cyclobutanes; Diabetes Mellitu	2006
[Pharmacotherapy for weight loss in patients with type 2 diabetes]. Ugeskrift for laeger, 2007, Aug-13, Volume: 169, Issue:33 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based M	2007
Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox. Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2008, Volume: 21, Issue:3 Topics: Adult; Appetite Depressants; Body Mass Index; Combined Modality Therapy; Cyclobutanes; Diabetes Mell	2008
[Pharma-clinics. Medication of the month. Sibutramine (Reductil)]. Revue medicale de Liege, 2001, Volume: 56, Issue:9 Topics: Appetite Depressants; Blood Pressure; Clinical Trials as Topic; Constipation; Cyclobutanes; Diabetes	2001

sibutramine and Diabetes Mellitus, Adult-Onset